Arylesterase and paraoxonase activity of paraoxonase (PON1) affected by ischemia in the plasma of patients with arterial occlusion of the lower limbs

Clinical Biochemistry

Volumn 42, Issue 1-2, 2009, Pages 50-56

  Kasprzak, Magdalena ^a   Iskra, Maria ^a   Majewski, Wacław ^a   Wielkoszyński, Tomasz ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Acute phase proteins; Atherosclerosis; Ischemia; Oxidative stress; Paraoxonase; PON1

Indexed keywords

ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; ALPHA 2 MACROGLOBULIN; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; C REACTIVE PROTEIN; CARBONYL DERIVATIVE; CERULOPLASMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MALONALDEHYDE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HYPERCHOLESTEROLEMIA; LIMB ISCHEMIA; MALE; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLASMA; PRIORITY JOURNAL; PROTEIN CARBONYLATION; ULTRAVIOLET SPECTROPHOTOMETRY;

AGED; ARTERIAL OCCLUSIVE DISEASES; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CARBOXYLIC ESTER HYDROLASES; HUMANS; ISCHEMIA; LOWER EXTREMITY; MALE; MIDDLE AGED;

EID: 57649102908     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.09.117     Document Type: Article

References (44)

1. Navab M., Ananthramaiah M., Reddy T., et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid Res. 45 (2004) 993-1007
2. Navab M., Berliner J., Subbanagounder G., et al. HDL, and inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler., Thromb., Vasc. Biol. 21 (2001) 481-488
3. Cao H., Girard-Globa A., Berthezene F., and Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q->R genetic polymorphism. J. Lipid Res. 40 (1999) 133-139
4. Aviram M., Rosenblat M., Bisgaier C., et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101 (1998) 1581-1590
5. Durrington P., Mackness B., and Mackness M. Paraoxonase and atherosclerosis. Arterioscler., Thromb., Vasc. Biol. 21 (2001) 473-480
6. Van Lenten B., Hama S., de Beer T., Diana F., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96 (1995) 2758-2767
7. Rienhoff H., Huang J., Li X., and Liao W. Molecular and cellular biology of serum amyloid A. Mol. Biol. Med. 7 (1990) 287-298
8. Chait A., Han C., Oram J., and Heinecke J. The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?. J. Lipid Res. 46 (2005) 389-403
9. Ng C., Shih D., Hama S., et al. The paraoxonase gene family and atherosclerosis. Free Radical Biol. Med. 38 (2005) 153-163
10. Deakin S., and James R. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. 107 (2004) 435-447
11. Laplaud P., Dantoine T., and Chapman J. Paraoxonase as a risk marker for cardiovascular disease: facts and hypotheses. Clin. Chem. Lab. Med. 36 (1998) 431-441
12. Abbott C., Mackness M., Kumar S., Boulton A., and Durrington P. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler., Thromb., Vasc. Biol. 15 (1995) 1812-1818
13. Mackness M., Harty M., Bhatnagar D., et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86 (1991) 193-199
14. Pasqualini L., Cortese C., Marchesi S., et al. Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 183 (2005) 349-354
15. Billecke S., Draganov D., Counsell R., et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos. 28 (2000) 1335-1342
16. Mackness B., Davies G., Turkie W., et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler., Thromb., Vasc. Biol. 21 (2001) 1451-1463
17. Davies G., Richter R., Keifer M., et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14 (1996) 334-336
18. Gan K., Smolen A., Eckerson H., and La Du B. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19 (1991) 100-106
19. Schosinsky H., Lehmann P., and Beeler F. Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin. Chem. 20 (1974) 1556-1563
20. Ohkawa H., Ohishi N., and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95 (1979 Jun) 351-358
21. Levine L., Williams J., Stadtman R., and Shacter E. Carbonyl assay for determination of oxidatively modified proteins. Methods Enzymol. 233 (1994) 346-357
22. Lowry H., Rosebrough J., Farr L., and Randal J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-276
23. Kutuk O., and Basaga H. Inflammation meets oxidation NF-κB, as a mediator of initial lesion development in atherosclerosis. Trends Mol. Med. 9 (2003) 535-549
24. Rumley A.G., Woodward M., Rumley A., Rumley J., and Lowe G.D. Plasma lipid peroxides: relationship to cardiovascular risk factors and prevalent cardiovascular disease. QJM 97 (2004) 809-816
25. Ferretti G., Bacchetti T., Nègre-Salvayre A., et al. Structural modifications of HDL and functional consequences. Atherosclerosis 184 (2006) 1-7
26. Van Lenten B.J., Hama S.Y., de Beer F.C., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. J. Clin. Invest. 96 (1995) 2758-2767
27. Nevin N., Zambon A., Furlong E., et al. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 1243-1249
28. Blatter Garin M.C., Moren X., and James R. Paraoxonase-1 and serum concentration of HDL-cholesterol and apoA-1. J. Lipid Res. 47 (2005) 515-520
29. Sumegova K., Blazicek P., Waczulikowa I., Zitnanova I., and Durackova Z. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks. Acta Biochim. Pol. 53 (2006) 783-787
30. Ayub A., Mackness M., Arrol S., Mackness B., Patel J., and Durrington P. Serum paraoxonase after myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 330-335
31. Mackness M., Arrol S., and Durrignton P. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286 (1991) 152-154
32. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 2 (1999) 115-126
33. Páramo J., Orbe J., and Fernández J. Fibrinolysis/proteolysis balance in stable angina pectoris in relation to angiographic findings. Thromb. Haemostasis 86 (2001 Aug) 636-639
34. Oleksyszyn J., and Augustine A. Plasminogen modulation of IL-1-stimulated degradation in bovine and human articular cartilage explants. The role of the endogenous inhibitors: PAI-1, alpha 2-antiplasmin, alpha 1-PI, alpha 2-macroglobulin and TIMP. Inflammation Res. 45 (1996 Sep) 464-472
35. Bogdański P., Chyrek R., Pupek-Musielak D., and Jabłecka A. Evaluation of selected acute phase proteins in patients with metabolic syndrome. Pol. Merkur. Lekarski 21 (2006 Jul) 12-14
36. 2 macroglobulin) and immunosenescence. Exp. Gerontol. 41 (2006) 1094-1107
37. Iskra M., and Majewski W. Oxidase activity of ceruloplasmin and concentrations of copper and zinc in serum in chronic arterial occlusion of the lower limbs. J. Trace Elem. Med. Biol. 13 (1999) 76-81
38. Borth W. Alpha 2-macroglobulin a multifunctional binding protein with targeting characteristics. FASEB J. 6 (1992) 3345-3353
39. Klipstein-Grobusch K., Grobbee D., and Koster J. Serum caeruloplasmin as a coronary risk factor in the elderly: the Rotterdam Study. Br. J. Nutr. 81 (1999) 139-144
40. Reunanen A., Knekt P., and Aaran R. Serum ceruloplasmin level and the risk of myocardial infarction and stroke. Am. J. Epidemiol. 136 (1992) 1082-1090
41. Majewski W., Iskra M., Stanisic M., Laciak M., Mackiewicz A., and Staniszewski R. The importance of ceruloplasmin oxidase activity in patients with chronic lower limb atherosclerotic ischemia. Int. Angiol. 26 4 (2007 Dec) 341-345
42. Mackness B., Hine D., McElduff P., and Mackness M. High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis 186 (2006) 396-401
43. Gur M., Aslan M., Yildiz A., et al. Paraoxonase and arylesterase activities in coronary artery disease. Eur. J. Clin. Invest. 36 (2006) 779-787
44. Gur M., Yildiz A., Demirbag R., et al. Paraoxonase and arylesterase activities in patients with cardiac syndrome X, and their relationship with oxidative stress markers. Coron. Artery Dis. 18 (2007) 89-95